🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Has anyone dealt with tirzepatide dual agonism: gip + glp-1 synergistic mechanism? Page 7

Has anyone dealt with tirzepatide dual agonism: gip + glp-1 synergistic mechanism?

robert_kc Fri, Apr 5, 2024 at 12:28 AM 49 replies 2,765 viewsPage 7 of 10
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
Aug 27, 2024 at 4:09 PM#31
PedsEndoPhilly said:
Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…

There is a second half to this that has not been said yet. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Last edited: Aug 27, 2024 at 9:09 PM
18 16JakeSmashed95, NauseaFreeNow, SteveThurs and 15 others
Reply Quote Save Share Report
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Sep 7, 2024 at 11:23 PM#32

The figures, for anyone assembling their own picture. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

Last edited: Sep 8, 2024 at 3:23 AM
19 17NicoleRaleigh, james_edin, FranDenver and 16 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Sep 19, 2024 at 6:30 AM#33

A narrower follow-up, since the general answer is now clear:

What would you measure differently if you were starting again?

20 18COA_Karl, MikeFit_NJ, InsuranceTom and 17 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Sep 30, 2024 at 1:31 PM#34
dave_SLC said:
Worth stating the units and the reference range whenever you post a number here.

I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.

Last edited: Sep 30, 2024 at 6:31 PM
21 19LibrarianMeg, bri_stats, pete_manc_UK and 18 others
Reply Quote Save Share Report
SteveThurs
Member
523
2,345
Sep 2024
Wisconsin
Online
Oct 11, 2024 at 8:25 PM#35
dave_SLC said:
Worth stating the units and the reference range whenever you post a number here.

That is right, and it stops being right at the edges. The general case is well behaved; the interesting cases in this thread are all at the boundary where the general case breaks.

Worth separating that from the pharmacology, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

22 20TomTeleRx, DoseLogDan, SleepFixSam and 19 others
Reply Quote Save Share Report

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register